HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment (Companion Faculty Lecture)

Research To Practice | Oncology Videos · Oct 13, 2025 · 31m

Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics:

Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00)

Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18)

Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10)

CME information and select publications